Drug Trial Radar · NCT07025044
Assessing the Genitourinary Microbiome of Women With Overactive Bladder Undergoing Onabotulinum Toxin Type A Intradetrusor Injections
Last checked: Nov 20, 2026Latest source record: Sep 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Sep 3, 2025
Primary completion
Dec 31, 2025
Study completion Jun 1, 2026
Sponsor
- Lead sponsor
- Alexis DieterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Medstar Health Research Institute
- First posted
- Jun 17, 2025
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Single-site prospective observational pilot feasibility study of women with overactive bladder/urge urinary incontinence undergoing onabotulinum toxin type A intradetrusor injections in order to achieve the following objectives: * Establish a record of successful collaboration with Dr. Ravel, an expert researcher in the female microbiome based at the University of Maryland * Demonstrate the investigators' ability to recruit subjects from the diverse population of postmenopausal women undergoing BTX for OAB within MedStar Health Urogynecology clinics * Collect, process and analyze urine specimens collected prior to and 4-weeks after BTX injection, and to compare the GU microbiome of self-collected versus clinic-collected samples * Assess response to BTX treatment and explore rates of and risk factors for urinary tract infection and incomplete voiding requiring catheterization within the first 4-weeks after BTX
Conditions
- Overactive Bladder (OAB)
- Urge Incontinence
Interventions
onabotulinum toxin type aDrug
All subjects will be scheduled to undergo Onabotulinum toxin type A intradetrusor injection for management of OAB. On Day 0, subjects will undergo Onabotulinum toxin type A injection by a licensed clinical provider and receive a one-time dose of Nitrofurantoin for infection prevention per standard clinic protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- RecruitmentTime frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
MedStar Urogynecology Clinic
Washington D.C., District of Columbia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.